Navellier & Associates’s ClearPoint Neuro CLPT Stock Holding History

Navellier & Associates’s Portfolio CLPT Stock Details CLPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$455K	Hold	50,000	–	–	0.05%	226
2025 Q4	$684K	Hold	50,000	–	–	0.08%	182
2025 Q3	$1.09M	Hold	50,000	–	–	0.11%	168
2025 Q2	$597K	Hold	50,000	–	–	0.07%	196
2025 Q1	$694K	Hold	50,000	–	–	0.1%	172
2024 Q4	$769K	Hold	50,000	–	–	0.09%	196
2024 Q3	$561K	Hold	50,000	–	–	0.08%	200
2024 Q2	$270K	Hold	50,000	–	–	0.03%	296
2024 Q1	$340K	Buy	+50,000	New	+$349K	0.04%	279

Other funds holding CLPT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

MCO

MAK Capital One New York $679M AUM 29.02% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Lane Generational Dover, Massachusetts $126M AUM 53.89% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

SG Americas Securities New York $92.9B AUM 36.98% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return

Navellier & Associates's CLPT Position: Q1 2026 in Review

Navellier & Associates held its ClearPoint Neuro (CLPT) position steady in Q1 2026 at 50,000 shares worth $455K. The position accounts for 0.05% of the portfolio, ranked #226.

Navellier & Associates first reported a position in CLPT in Q1 2024 and has held it in 9 quarters since. The position peaked at $1.09M in Q3 2025. 118 funds tracked by Wall St. Rank hold CLPT as of Q1 2026.

Navellier & Associates held 50,000 shares of ClearPoint Neuro worth $455K as of Q1 2026.
Navellier & Associates left its ClearPoint Neuro share count unchanged in Q1 2026.
ClearPoint Neuro made up 0.05% of Navellier & Associates's portfolio in Q1 2026, its #226 holding.
Navellier & Associates first reported a position in ClearPoint Neuro in Q1 2024 and has held it in 9 quarters since.
Navellier & Associates's ClearPoint Neuro position peaked at $1.09M in Q3 2025.
118 funds tracked by Wall St. Rank held ClearPoint Neuro as of Q1 2026.

Based on Navellier & Associates's 13F filing for Q1 2026, filed 7 May 2026.